drugset
Drugs / Methoxyamine
last change Dec 2022 re-read 9 days ago

Methoxyamine

also known as TRC102 · Methoxyamine hcl · Methoxyamine Hydrochloride · NSC-3801

Small molecule

Developed for
lung adenocarcinoma · lung large cell carcinoma · adult glioblastoma · adult T-cell leukemia/lymphoma · anaplastic large cell lymphoma · angioimmunoblastic T-cell lymphoma · Burkitt lymphoma · cancer of unknown primary site
+23 more · chronic lymphocytic leukemia/small lymphocytic lymphoma · chronic myeloid leukemia · extranodal nasal NK/T cell lymphoma · grade III lymphomatoid granulomatosis · hepatosplenic T-cell lymphoma · Hodgkins lymphoma · intraocular lymphoma · large-cell immunoblastic lymphoma · lymphoblastic lymphoma · malignant peritoneal mesothelioma · malignant pleural mesothelioma · MALT lymphoma · mantle cell lymphoma · mycosis fungoides and variants · nodal marginal zone B-cell lymphoma · peripheral T-cell lymphoma, not otherwise specified · plasma cell myeloma · primary cutaneous B-cell lymphoma · small intestine lymphoma · splenic marginal zone lymphoma · testicular lymphoma · Waldenstrom macroglobulinemia · non-small cell lung carcinoma
Investigated by
National Cancer Institute (NCI) · Case Comprehensive Cancer Center

Trials 6

today NCT05198830 · Ph 2 NCT02535312 · Ph 1/2 NCT02395692 · Ph 2 NCT02535325 · Ph 1 NCT01658319 · Ph 1 NCT00892385 · Ph 1
200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT02535325 Sep 2015 → Feb 2020 lung adenocarcinoma, lung large cell carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT01658319 May 2011 → Feb 2015 Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia +20 Case Comprehensive Cancer Center Completed No outcome recorded
Phase 1 NCT00892385 Aug 2007 → Mar 2017 cancer of unknown primary site Case Comprehensive Cancer Center Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02535312 Mar 2016 → Dec 2022 overdue malignant peritoneal mesothelioma, malignant pleural mesothelioma National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 22 trials
Phase 2 NCT05198830 Dec 2022 → Jun 2027 expected lung adenocarcinoma, lung large cell carcinoma National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 2 NCT02395692 Dec 2015 → Feb 2017 adult glioblastoma National Cancer Institute (NCI) Terminated No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Methoxyamine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02535312 ↗
5

NCT02535325 ↗

NCT02395692 ↗

NCT00892385 ↗

NCT01658319 ↗

NCT05198830 ↗
Known as Methoxyamine hcl ChEMBL registry synonym — accepted as the source's own label CHEMBL1213633 ↗
Known as Methoxyamine Hydrochloride “Drug: Methoxyamine Hydrochloride” NCT02535325 ↗
Known as NSC-3801 ChEMBL registry synonym — accepted as the source's own label CHEMBL1213633 ↗
Known as TRC102 “This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation...” NCT05198830 ↗
1

“methoxyamine (TRC102)” NCT02535312 ↗
Modality Small molecule — CHEMBL1213633 ↗
Route Intravenous “MX will be given as a single one-hour IV infusion every 28 days.” NCT00892385 ↗